Legal & General Group
BNTC icon

Legal & General Group’s Benitec Biopharma BNTC Stock Holding History

Legal & General Group’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6K Buy
1,746
+214
+14% +$2.48K ﹤0.01% 2985
2025
Q4 		$20.6K Sell
1,532
-81
-5% -$1.12K ﹤0.01% 3014
2025
Q3 		$22.6K Hold
1,613
– – ﹤0.01% 2996
2025
Q2 		$18.9K Buy
+1,613
New +$22.6K ﹤0.01% 3027

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Legal & General Group's BNTC Position: Q1 2026 in Review

Legal & General Group increased its Benitec Biopharma (BNTC) stake by 14% in Q1 2026, buying an estimated $2.48K and bringing the position to 1,746 shares worth $18.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

Legal & General Group first reported a position in BNTC in Q2 2025 and has held it in 4 quarters since. The position peaked at $22.6K in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Legal & General Group held 1,746 shares of Benitec Biopharma worth $18.6K as of Q1 2026.
  • Legal & General Group bought 214 Benitec Biopharma shares in Q1 2026, an estimated $2.48K.
  • Benitec Biopharma made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2985 holding.
  • Legal & General Group first reported a position in Benitec Biopharma in Q2 2025 and has held it in 4 quarters since.
  • Legal & General Group's Benitec Biopharma position peaked at $22.6K in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.